Johnson & Johnson (NYSE:JNJ) Shares Purchased by Berry Wealth Group LP

Berry Wealth Group LP grew its stake in shares of Johnson & Johnson (NYSE:JNJ) by 4.4% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 18,478 shares of the company’s stock after acquiring an additional 771 shares during the quarter. Johnson & Johnson accounts for 2.2% of Berry Wealth Group LP’s portfolio, making the stock its 13th largest position. Berry Wealth Group LP’s holdings in Johnson & Johnson were worth $2,701,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in JNJ. Citizens & Northern Corp increased its position in shares of Johnson & Johnson by 3.5% during the second quarter. Citizens & Northern Corp now owns 1,884 shares of the company’s stock worth $275,000 after acquiring an additional 63 shares during the last quarter. Carolinas Wealth Consulting LLC increased its holdings in Johnson & Johnson by 0.4% during the 4th quarter. Carolinas Wealth Consulting LLC now owns 16,861 shares of the company’s stock worth $2,643,000 after purchasing an additional 64 shares during the last quarter. Epic Trust Investment Advisors LLC raised its position in shares of Johnson & Johnson by 3.6% in the 2nd quarter. Epic Trust Investment Advisors LLC now owns 1,831 shares of the company’s stock valued at $268,000 after purchasing an additional 64 shares in the last quarter. Verity Asset Management Inc. boosted its stake in shares of Johnson & Johnson by 2.0% during the 4th quarter. Verity Asset Management Inc. now owns 3,268 shares of the company’s stock valued at $512,000 after buying an additional 65 shares during the last quarter. Finally, Outfitter Financial LLC increased its stake in shares of Johnson & Johnson by 0.4% in the second quarter. Outfitter Financial LLC now owns 16,632 shares of the company’s stock worth $2,431,000 after buying an additional 65 shares during the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

JNJ has been the topic of a number of research analyst reports. TD Cowen reduced their price objective on shares of Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating on the stock in a research note on Thursday, July 18th. Daiwa Capital Markets downgraded Johnson & Johnson from an “outperform” rating to a “neutral” rating and decreased their price target for the stock from $160.00 to $150.00 in a research note on Tuesday, July 23rd. Daiwa America cut Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 23rd. Morgan Stanley lifted their target price on Johnson & Johnson from $167.00 to $169.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 18th. Finally, The Goldman Sachs Group dropped their price target on Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating on the stock in a research report on Friday, July 19th. Seven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and an average target price of $173.21.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ opened at $165.86 on Tuesday. Johnson & Johnson has a 12-month low of $143.13 and a 12-month high of $165.98. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.44. The company has a market cap of $399.17 billion, a PE ratio of 10.34, a P/E/G ratio of 2.73 and a beta of 0.52. The stock has a 50 day simple moving average of $156.02 and a 200-day simple moving average of $153.53.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.71 by $0.11. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The company had revenue of $22.45 billion during the quarter, compared to analysts’ expectations of $22.33 billion. During the same quarter in the prior year, the business posted $2.80 earnings per share. The company’s revenue for the quarter was up 4.3% compared to the same quarter last year. On average, equities research analysts forecast that Johnson & Johnson will post 10.02 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th will be issued a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 2.99%. The ex-dividend date is Tuesday, August 27th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 30.92%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.